Slide 12 has the breakdown of patient numbers and notes 375 is the annual number of USA pediatric patients with SR-aGvHD. Whilst MSB will only treat a % of this number this year, SI did mention again today that for these patients Ryoncil under the EAP was effectively the SOC.
It seems that revenue may soon equal or exceed costs, even before label expansion and progress with Rex.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.010(0.62%) |
Mkt cap ! $2.070B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.66 | $1.60 | $6.344M | 3.894M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 102178 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.63 | 52607 | 2 |
View Market Depth
| Last trade - 16.12pm 26/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |